Welcome to LookChem.com Sign In|Join Free
  • or
Home > Products >  > 

Ouabain

Related Products

Hot Products

Name

Ouabain

EINECS 211-139-3
CAS No. 630-60-4 Density 1.52 g/cm3
PSA 206.60000 LogP -1.51500
Solubility Soluble in water, boiling water, ethanol, boiling ethanol, pentanol and dioxane. Slightly soluble in ethyl ether, chloroform and ethyl acetate Melting Point 200°C
Formula C29H44O12 Boiling Point 838.219 °C at 760 mmHg
Molecular Weight 584.661 Flash Point 272.893 °C
Transport Information UN 1544 6.1/PG 1 Appearance Odorless, white crystals or crystalline powder as an octahydrate
Safety 45 Risk Codes 23/25-33
Molecular Structure Molecular Structure of 630-60-4 (G-STROPHANTHIN) Hazard Symbols ToxicT
Synonyms

Ouabain(8CI);Acocantherin;Astrobain;Gratibain;Gratus strophanthin;Kombetin;NSC 25485;Ouabaine;Purostrophan;Rectobaina;Solufantina;Strodival;Strophalen;Strophoperm;Strophosan;Uabaina;Uabanin;g-Strophanthin;(1β,3β,5β,11α)-3-[(6-Deoxy-α-L-mannopyranosyl)oxy]-1,5,11,14,19-pentahydroxycard-20(22)-enolide;Card-20(22)-enolide,3-[(6-deoxy-a-L-mannopyranosyl)oxy]-1,5,11,14,19-pentahydroxy-,(1b,3b,5b,11a)-;1β,3β,5β,11α,14,19-Hexahydroxycard-20(22)-enolide 3-(6-deoxy-α-L-mannopyranoside);

Article Data 1

Ouabain Synthetic route

1018988-68-5

C52H58O16

630-60-4

ouabain

Conditions
ConditionsYield
With sodium carbonate In methanol at 20℃; for 1h;88%
630-60-4

ouabain

27607-77-8

trimethylsilyl trifluoromethanesulfonate

1α,2',3',11α,19-hexa-[(trimethylsilyl)oxy]-3β-[(α-L-rhamnopyranosyl)oxy]-5,14-dihydroxycard-20(22)-enolide

Conditions
ConditionsYield
With pyridine at 20℃; for 1h;95%
630-60-4

ouabain

C29H42O12

Conditions
ConditionsYield
With 4-methyl-morpholine; 6C6H15P*4CF3O3S(1-)*2Ru(2+); acetone at 65℃; for 3.5h; Inert atmosphere; Sealed tube;92%
630-60-4

ouabain

931-94-2

1,1-dimethoxycyclopentane

C34H50O12

Conditions
ConditionsYield
With toluene-4-sulfonic acid In tetrahydrofuran at 23℃; for 16h;91%
630-60-4

ouabain

67-64-1

acetone

326805-71-4

4-((3R,3aR,5R,5aS,5bR,9aR,11S,12aS,14aR,14bS)-5,12a,14b-trihydroxy-11-(((3aR,4R,6S,7S,7aR)-7-hydroxy-2,2,6-trimethyltetrahydro-4H-[1,3]dioxolo[4,5-c]pyran-4-yl)oxy)-3a,8,8-trimethylhexadecahydro-6H-cyclopenta[7,8]phenanthro[4,4a-d][1,3]dioxin-3-yl)furan-2(5H)-one

Conditions
ConditionsYield
With hydrogenchloride at 25℃; for 2h;89%
With hydrogenchloride at 20℃;84%
With hydrogenchloride In water at 20℃; for 2h;84%
630-60-4

ouabain

108-24-7

acetic anhydride

57198-85-3

(2R,3R,4R,5S,6S)-2-(((1R,3S,5S,10R,11R,13R,14S,17R)-1,11-diacetoxy-10-(acetoxymethyl)-5,14-dihydroxy-13-methyl-17-(5-oxo-2,5-dihydrofuran-3-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-6-methyltetrahydro-2H-pyran-3,4,5-triyl triacetate

Conditions
ConditionsYield
Reflux;88%
for 1.5h; Heating;71%
With pyridine
630-60-4

ouabain

80522-42-5

triisopropylsilyl trifluoromethanesulfonate

292068-65-6

3',19-di-[(triisopropylsilyl)oxy]-3β-[(α-L-rhamnopyranosyl)oxy]-1β,5,11α,14-tetrahydroxycard-20(22)-enolide

Conditions
ConditionsYield
With 1H-imidazole In N,N-dimethyl-formamide for 1.5h;88%
With pyridine at 20℃; for 1h;33%
630-60-4

ouabain

80522-42-5

triisopropylsilyl trifluoromethanesulfonate

1β,3',19-tri-[(triisopropylsilyl)oxy]-3β-[(α-L-rhamnopyranosyl)oxy]-5,11α,14-trihydroxycard-20(22)-enolide

Conditions
ConditionsYield
With pyridine at 20℃; for 1h;87%
630-60-4

ouabain

1042149-56-3

(Z)-4-hydroxy-3-((1R,3S,5S,8R,9S,10R,11R,13R,14S,17R)-1,5,11,14-tetrahydroxy-10-(hydroxymethyl)-13-methyl-3-((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)but-2-enoic acid

Conditions
ConditionsYield
With lithium hydroxide In tetrahydrofuran at 20℃; Saponification;79%
630-60-4

ouabain

70122-89-3

tert-butyl allyl carbonate

C32H48O12

Conditions
ConditionsYield
Stage #1: ouabain With dihydroxy-methyl-borane In tetrahydrofuran; isopropyl alcohol Glovebox; Inert atmosphere;
Stage #2: tert-butyl allyl carbonate With tris(dibenzylideneacetone)dipalladium chloroform complex; triphenylphosphine In tetrahydrofuran; isopropyl alcohol at 25℃; for 16.16h; Glovebox; Inert atmosphere; Sealed tube;
74%

Ouabain Consensus Reports

EPA Extremely Hazardous Substances List. Reported in EPA TSCA Inventory.

Ouabain Specification

The Ouabain, with the CAS registry number 630-60-4, is also known as G-Strophanthin. It belongs to the product categories of Biochemistry; Glycosides; Rhamnose; Steroidglycosides; Steroids; Sugars. Its EINECS number is 211-139-3. This chemical's molecular formula is C29H44O12 and molecular weight is 584.65. What's more, its systematic name is (1β,3β,5β,11α)-3-[(6-Deoxy-α-L-mannopyranosyl)oxy]-1,5,11,14,19-pentahydroxycard-20(22)-enolide. Its classification codes are: (1)Cardiotonic agents; (2)Cardiovascular Agents; (3)Drug / Therapeutic Agent; (4)Enzyme inhibitors; (5)Mutation data; (6)Natural Product; (7)Protective Agents. This chemical is used to produce rapid digitalization in acute congestive heart failure, and it is also recommended in treatment of atrial or nodal paroxysmal tachycardia and atrial flutter. It is a cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae. It should be sealed and stored in a cool and dry place. Moreover, it should be protected from oxides. 

Physical properties of Ouabain are: (1)ACD/LogP: -2.205; (2)# of Rule of 5 Violations: 3; (3)ACD/LogD (pH 5.5): -2.21; (4)ACD/LogD (pH 7.4): -2.21; (5)ACD/BCF (pH 5.5): 1.00; (6)ACD/BCF (pH 7.4): 1.00; (7)ACD/KOC (pH 5.5): 1.51; (8)ACD/KOC (pH 7.4): 1.51; (9)#H bond acceptors: 12; (10)#H bond donors: 8; (11)#Freely Rotating Bonds: 12; (12)Polar Surface Area: 206.6 Å2; (13)Index of Refraction: 1.655; (14)Molar Refractivity: 141.172 cm3; (15)Molar Volume: 384.679 cm3; (16)Polarizability: 55.965×10-24cm3; (17)Surface Tension: 83.78 dyne/cm; (18)Density: 1.52 g/cm3; (19)Flash Point: 272.893 °C; (20)Enthalpy of Vaporization: 138.556 kJ/mol; (21)Boiling Point: 838.219 °C at 760 mmHg; (22)Vapour Pressure: 0 mmHg at 25°C.

Uses of Ouabain: it can be used to produce 1b,3',19-tri-[(tert-butyldimethylsilyl)oxy]-3b-[(a-L-rhamnopyranosyl)oxy]-5,11a,14-trihydroxycard-20(22)-enolide. It will need reagent imidazole and solvent dimethylformamide with the reaction time of 2 hours. The yield is about 72%.

Ouabain can be used to produce 1b,3',19-tri-[(tert-butyldimethylsilyl)oxy]-3b-[(a-L-rhamnopyranosyl)oxy]-5,11a,14-trihydroxycard-20(22)-enolide

When you are using this chemical, please be cautious about it as the following:
This chemical is toxic by inhalation and if swallowed. In case of accident or if you feel unwell, you should seek medical advice immediately (show the label where possible).

You can still convert the following datas into molecular structure:
(1)SMILES: O=C\1OC/C(=C/1)[C@H]2CC[C@@]6(O)[C@]2(C)C[C@@H](O)[C@H]4[C@H]6CC[C@]5(O)C[C@@H](O[C@@H]3O[C@H]([C@H](O)[C@@H](O)[C@H]3O)C)C[C@@H](O)[C@]45CO
(2)Std. InChI: InChI=1S/C29H44O12/c1-13-22(34)23(35)24(36)25(40-13)41-15-8-19(32)28(12-30)21-17(3-5-27(28,37)9-15)29(38)6-4-16(14-7-20(33)39-11-14)26(29,2)10-18(21)31/h7,13,15-19,21-25,30-32,34-38H,3-6,8-12H2,1-2H3/t13-,15-,16+,17+,18+,19+,21+,22-,23+,24+,25-,26+,27-,28+,29-/m0/s1
(3)Std. InChIKey: LPMXVESGRSUGHW-HBYQJFLCSA-N

The toxicity data is as follows:

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
cat LD50 intraperitoneal 100ug/kg (.1mg/kg)   Archives Internationales de Pharmacodynamie et de Therapie. Vol. 155, Pg. 165, 1965.
cat LD50 intravenous 100ug/kg (.1mg/kg)   Proceedings of the Society for Experimental Biology and Medicine. Vol. 35, Pg. 316, 1936.
cat LDLo intraduodenal 820ug/kg (.82mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 8, Pg. 557, 1958.
cat LDLo oral 5mg/kg (5mg/kg)   Farmacognosia. Vol. 13, Pg. 375, 1953.
cat LDLo subcutaneous 150ug/kg (.15mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 23, Pg. 1125, 1973.
cat LDLo unreported 90ug/kg (.09mg/kg)   Archives Internationales de Pharmacodynamie et de Therapie. Vol. 148, Pg. 471, 1964.
dog LDLo intravenous 54ug/kg (.054mg/kg) CARDIAC: CHANGE IN RATE Journal of Pharmacology and Experimental Therapeutics. Vol. 179, Pg. 447, 1971.
dog LDLo oral 1500ug/kg (1.5mg/kg)   "Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1289, 1935.
dog LDLo subcutaneous 100ug/kg (.1mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 23, Pg. 1125, 1973.
frog LD50 intravenous 250ug/kg (.25mg/kg)   Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 61, Pg. 231, 1965.
frog LD50 parenteral 370ug/kg (.37mg/kg)   Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 53, Pg. 995, 1957.
frog LDLo subcutaneous 400ug/kg (.4mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 23, Pg. 1125, 1973.
guinea pig LD50 intraperitoneal 210ug/kg (.21mg/kg)   Acta Biologica et Medica Germanica. Vol. 12, Pg. 434, 1964.
guinea pig LD50 intravenous 228ug/kg (.228mg/kg)   Acta Biologica et Medica Germanica. Vol. 12, Pg. 434, 1964.
guinea pig LD50 oral 8280ug/kg (8.28mg/kg)   United States Patent Document. Vol. #4230702,
guinea pig LD95 intraduodenal 3340ug/kg (3.34mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 8, Pg. 557, 1958.
guinea pig LDLo intraarterial 40ug/kg (.04mg/kg)   Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 131, Pg. 171, 1928.
guinea pig LDLo intramuscular 220ug/kg (.22mg/kg)   Journal of Pharmacology and Experimental Therapeutics. Vol. 52, Pg. 1, 1934.
guinea pig LDLo subcutaneous 100ug/kg (.1mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 23, Pg. 1125, 1973.
monkey LDLo intravenous 102ug/kg (.102mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 13, Pg. 412, 1963.
mouse LD50 intracrebral 69ug/kg (.069mg/kg) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD Pharmacological Research Communications. Vol. 6, Pg. 417, 1974.
mouse LD50 intraperitoneal 11mg/kg (11mg/kg)   Archives Internationales de Pharmacodynamie et de Therapie. Vol. 155, Pg. 165, 1965.
mouse LD50 intravenous 2200ug/kg (2.2mg/kg)   Proceedings of the Society for Experimental Biology and Medicine. Vol. 118, Pg. 756, 1965.
mouse LD50 oral 5mg/kg (5mg/kg)   Japanese Journal of Toxicology. Vol. 4, Pg. 105, 1991.
mouse LD50 subcutaneous 5mg/kg (5mg/kg)   Japanese Journal of Toxicology. Vol. 4, Pg. 105, 1991.
pigeon LDLo intramuscular 330ug/kg (.33mg/kg)   Comptes Rendus Hebdomadaires des Seances, Academie des Sciences. Vol. 149, Pg. 306, 1909.
pigeon LDLo intravenous 183ug/kg (.183mg/kg) CARDIAC: CHANGE IN RATE

GASTROINTESTINAL: NAUSEA OR VOMITING

CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION)
Archives Internationales de Pharmacodynamie et de Therapie. Vol. 126, Pg. 412, 1960.
pigeon LDLo oral 14mg/kg (14mg/kg)   Comptes Rendus Hebdomadaires des Seances, Academie des Sciences. Vol. 149, Pg. 306, 1909.
rabbit LD50 intravenous 252ug/kg (.252mg/kg)   Pharmacological Research Communications. Vol. 13, Pg. 571, 1981.
rabbit LDLo intramuscular 1mg/kg (1mg/kg)   Comptes Rendus Hebdomadaires des Seances, Academie des Sciences. Vol. 149, Pg. 306, 1909.
rabbit LDLo oral 7mg/kg (7mg/kg)   Comptes Rendus Hebdomadaires des Seances, Academie des Sciences. Vol. 149, Pg. 306, 1909.
rabbit LDLo subcutaneous 100ug/kg (.1mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 23, Pg. 1125, 1973.
rat LD50 intravenous 14mg/kg (14mg/kg)   Toxicology and Applied Pharmacology. Vol. 20, Pg. 44, 1971.
rat LD50 unreported 125mg/kg (125mg/kg)   Toxicology and Applied Pharmacology. Vol. 22, Pg. 336, 1972.
rat LDLo subcutaneous 50mg/kg (50mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 23, Pg. 1125, 1973.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 630-60-4